HCW 2026: Switzerland based Oculis focuses today on neuro-ophthalmology, which has led them to a pivotal trial in optic neuritis and key mid-stage data coming this year in dry eye disease
CEO Riad Sherif describes the phase 2 data Oculis delivered in optic neuritis with privosegtor last year and he previews data the company will have soon for licaminlamab in dry eye.
Coverage brought to you by











.png)